secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0000950170-25-100228
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q2 revenue $157.4M (+38% YoY), net income $34.9M; raises FY2025 guidance
--------------------------------------------------------------------------------

- Revenue $157.4M vs $114.3M YoY (+38%); net income $34.9M ($0.92 diluted EPS) vs $12.2M.
- Raises full-year 2025 revenue guidance to $585M-$605M from $565M-$585M (35% midpoint growth).
- Gross margin 61% consistent YoY; operating expenses $60.0M up from $56.8M on R&D investment.
- Cash $400.6M; received conditional IDE approval from FDA for Next-Gen OCS Lung trial.
- Launched OCS NOP digital ecosystem NOP ACCESS across major U.S. transplant programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017025100228/0000950170-25-100228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017025100228/tmdx-20250730.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-100228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer